Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2003
11/06/2003WO2003090746A1 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
11/06/2003WO2003090732A1 Lxr modulators for the treatment of cardiovascular diseases
11/06/2003WO2003090695A2 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
11/06/2003WO2003090689A2 Neurodegenerative disorder treatment using gdnf secreting neural cells
11/06/2003WO2003090684A2 Polymer compositions containing a macrocyclic triene compound
11/06/2003WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003WO2003090665A2 Regulation of erythrocyte apoptosis
11/06/2003WO2003090640A2 Microbial cellulose wound dressing for treating chronic wounds
11/06/2003WO2003090547A1 A composition comprising waxy acids for effecting serum cholesterol levels
11/06/2003WO2003090512A2 Regeneration of endogenous myocardial tissue by induction of neovascularization
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003076458A3 Selective dipeptide inhibitors of kallikrein
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003068153A3 CARDIAC-SPECIFIC 11β HYDROXYSTEROID DEHYDROGENASE TYPE 2 TRANSGENIC MICE
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003055983A3 Targeted retrograde gene delivery to motor neurons
11/06/2003WO2003055880A3 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
11/06/2003WO2003054541A3 Inhibition of tristetraproline for protection of the heart from cardiac injuries
11/06/2003WO2003054009A3 Apoptotically active peptides
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003032901A3 Pathological tissue detection and treatment employing targeted benzoindole optical agents
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003013549A3 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
11/06/2003WO2003013420A3 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin
11/06/2003WO2002094799A3 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/06/2003WO2002083083A3 Pharmaceutically active compounds and methods of use
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002076482B1 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
11/06/2003WO2002072100A3 Pharmaceutical composition containing pde v inhibitors and surfactants
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
11/06/2003WO2002060949A8 Glycoforms a fas ligand inhibitory protein analog
11/06/2003WO2002060900A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002053742A3 Proteins and nucleic acids encoding same
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002044210A3 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
11/06/2003WO2002040039A3 In vivo use of water absorbent polymers
11/06/2003WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
11/06/2003WO2002026737A8 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2000033865A8 Methods of inhibiting ectopic calcification
11/06/2003US20030208261 Bulbous valve and stent for treating vascular reflux
11/06/2003US20030208249 Energy-activated targeted cancer therapy
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208082 Nitrogen compounds such as 4,5-diisopropyl-1-methyl-2-styryl -1H-imidazole, used as glutamate receptor antagonists, for prophylaxis of psychological disorders, as anxiolytic agents and analgesics
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208059 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208048 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030207944 Aminotetralin derivative for the therapy of cardiovascular diseases
11/06/2003US20030207941 Method of treating vascular endothelial growth factor mediated vascular disorders
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207930 Valsartan salts
11/06/2003US20030207925 Methods of treatment with selective EP4 receptor agonists
11/06/2003US20030207924 Compounds that modulate PPAR activity and methods of preparation
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207918 Administering to patient a bolus injection of an active drug, in particular tirofiban, in an amount of 25 mu g/kg, and administering to the patient, after the bolus injection, an intravenous infusion for a period of 12-72 hours of the drug
11/06/2003US20030207916 Thiazole or oxazole derivatives such as (4-(4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl)-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid
11/06/2003US20030207915 Compounds that modulate PPAR activity and methods of preparation
11/06/2003US20030207911 For treatment of disease associated with the adenosine A2 receptor such as Alzheimer's disease and Parkinson's disease
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207898 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders
11/06/2003US20030207895 Tissue factor antagonists and methods of use thereof
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207883 Indazole benzimidazole compounds
11/06/2003US20030207882 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207877 Pyridoquinoxaline antivirals
11/06/2003US20030207875 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207864 Novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular
11/06/2003US20030207860 Neuropeptide Y Y5 receptor antagonists
11/06/2003US20030207852 Treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment.
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207807 A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and a protein
11/06/2003US20030207447 Used to distinguish between arterial endothelial cells (arteries) and venous endothelial cells (veins)
11/06/2003US20030207435 Have increased anti-coagulation activity and resistance to inactivation by serpins
11/06/2003US20030207434 Phosphodiesterases
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207347 Useful in treating ovarian, renal, neurological, cardiovascular disorders and modulating angiogenesis, cell proliferation
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207293 Cryptic-like secreted protein
11/06/2003US20030207262 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
1 ... 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 ... 1595